|
Gary Krishnan, M.Sc., Ph.D.
KRISHNAN_GARY@Lilly.com
Senior Research Advisor, Eli Lilly & Co.
My research focuses on cell fate determination of bone marrow pluripotent
cells which are capable of differentiating into osteoblasts. We
approach this pathway using known inducers of osteoblast differentiation,
such as PTH, androgen, Vit D, BMP-4 and Ihh. These agents rely on
distinct signaling pathways, to elicit their osteogenic activity.
Their bone anabolic activity is a result of a combination of direct
targeting of osteoblasts and alterations in the extracellular matrix
surrounding the osteoblast.
In addition my lab focuses on the mechanism of action of selective
nuclear receptor modulators, which results in tissue selective targeting
of nuclear receptor action. We approach this selective modulation
with the help of known selective modulators, such as Raloxifene
and Tamoxifen which induce distinct structural conformations of
the estrogen receptor when bound to its ligand-binding domain. These
unique conformations are recognized by a set of coactivator or corepressor
proteins and ultimately decide the impact of the "selective
modulator" bound ER on the target gene within each responsive
tissue.
|
Department of Biology